Skip to main content

Advertisement

Table 5 Luminol enhanced whole blood chemiluminescence (LBCL) measured before and after polysomnography controlled sleep

From: No evidence of enhanced oxidant production in blood obtained from patients with obstructive sleep apnea

   Patients undergoing polysomnography
Chemiluminescence parameter Time of the day OSAS Severe OSAS CPAP-OSAS Controls
rCL [aU/104p] Evening 2.4 ± 2.2 1.9 ± 1.8 2.2 ± 1.9 1.9 ± 1.8
  Morning 2.3 ± 2.2 2.5 ± 2.8 1.5 ± 0.9 1.6 ± 1.5
  Diff and 95% CI 0.1 (-0.7 – 0.8) 0.6 (0.15 – 1.02) 0.7 (0.1 – 1.2) 0.2 (-0.1 – 0.5)
pCL [aU/104p] Evening 6.4 ± 5.1 4.9 ± 4.7 6.0 ± 4.4 5.5 ± 4.3
  Morning 5.9 ± 4.6 5.9 ± 4.8 4.3 ± 2.9 4.7 ± 2.5
  Diff and 95% CI 0.5 (-0.9 – 1.8) 0,9 (-0.4 – 2.2) 1.6 (0.4 – 2.9) 5.2 (-2,0 – 12.4)
tCL [aU·s/104p] Evening 1939 ± 1532 1503 ± 1391 1805 ± 1278 1642 ± 1316
  Morning 1790 ± 1371 1778 ± 1442 1313 ± 820 1416 ± 961
  Diff and 95% CI 149 (-275 – 573) 275 (-117 – 668) 492 (132 – 852) 225 (22 – 430)
Peak time [s] Evening 281 ± 31 276 ± 37 293 ± 30 270 ± 24
  Morning 275 ± 30 277 ± 37 284 ± 22 339 ± 23
  Diff and 95% CI 6 (0.3 – 11.5) 1 (-5.3 – 6.5) 9 (0.1 – 16.3) 69 (-22 – 160)
  1. rCl – the average resting chemiluminescence prior to addition of fMLP; pCL – maximal chemiluminescence signal after addition of fMLP; tCl – total light emission after cell stimulation with fMLP; peak time – the time from fMLP addition to the appearance of pCL; OSAS – patients with the untreated OSAS; Severe OSAS – patients with AHI ≥ 30; CPAP-OSAS – patients with OSAS treated successfully after a first attempt with CPAP, controls – subjects without OSAS Results expressed as mean ± SD, difference of means with 95% confidence interval (Diff and 95% CI) No significant differences (p > 0.05) were found for evening and morning LBCL parameters within and between the studied groups.